Akebia Therapeutics (AKBA) Stock Price, Quote & News

Company Profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 617 871 2098

Fax: 617 871 2099

Website: www.akebia.com

Address:

245 First Street, Suite 1400, Cambridge, United States

HarryA123 Aug. 4 at 3:09 AM

$AKBA 1.27 dawg.

1 · Reply

MB76 Aug. 3 at 10:10 PM

$AKBA So now when you post useful information showing the support our drug is receiving from a dialysis organization, it proves lackluster sales. You can’t make this stuff up. Desperation is all over this sad clowns posts!!!

4 · Reply

Noname2022 Aug. 3 at 9:50 PM

$AKBA Fresenius appears to be successfully managing anemia in roughly 7 out of 10 patients under its current treatment approach. https://freseniusmedicalcare.com/content/dam/fresenius-medical-care/global/en/03_investors/pdf/03_publications/2026/q2/FME_Q2_2026_Analyst_Presentation.pdf

3 · Reply

Harrisford222 Aug. 3 at 9:38 PM

$AKBA Thats nice but WHAT COUNTS are hard revenue numbers. No hopes or wet dreams. The fact we see posts like the one below are additional clues that Q2 ist again disappointing...

2 · Reply

IberianBullish Aug. 3 at 9:37 PM

$AKBA

0 · Reply

ROCKET123 Aug. 3 at 9:36 PM

$AKBA Well, Maybe patients don’t want to live longer, maybe they don’t want to stay out of the hospital…And Maybe doctors don’t want to change to Vafseo even though they know they are causing harm to their patients on ESA with each passing day…And Maybe dialysis center could just care less about their patients …hmmm💎

0 · Reply

Holy_boy Aug. 3 at 9:27 PM

$AKBA

4 · Reply

Noname2022 Aug. 3 at 9:09 PM

$CRMD $DVA $FMS $AKBA https://freseniusmedicalcare.com/content/dam/fresenius-medical-care/global/en/03_investors/pdf/03_publications/2026/q2/FME_Q2_2026_Analyst_Presentation.pdf

1 · Reply

Invest2live Aug. 3 at 8:57 PM

$CPIX 304% already; congrats 🔆🌿🌟 Checkout $HUMA and $AKBA excellent value now.

0 · Reply

MB76 Aug. 3 at 8:53 PM

$AKBA Clown still posting back and forth with himself!!!

1 · Reply

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-08-03T12:20:30.000Z - 15 hours ago

Akebia initiates ebribafusp basket trial

Aug 3, 2026, 8:00 AM EDT - 15 hours ago

Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases

Jul 29, 2026, 8:00 AM EDT - 5 days ago

Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights

Jul 2, 2026, 4:05 PM EDT - 4 weeks ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-06-30T12:31:42.000Z - 4 weeks ago

Akebia announces VOICE trial met predefined stopping criteria

Jun 30, 2026, 8:00 AM EDT - 4 weeks ago

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

Jun 17, 2026, 10:00 AM EDT - 6 weeks ago

Akebia Therapeutics Transcript: AGM 2026

2026-06-10T12:28:51.000Z - 7 weeks ago

Akebia announces new Vafseo patent

Jun 10, 2026, 8:00 AM EDT - 7 weeks ago

Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio

Jun 4, 2026, 7:35 AM EDT - 2 months ago

Akebia Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

May 28, 2026, 8:00 AM EDT - 2 months ago

Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

May 7, 2026, 8:00 AM EDT - 3 months ago

Akebia Therapeutics Earnings Call Transcript: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Akebia Therapeutics Earnings release: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Akebia Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

May 4, 2026, 8:00 AM EDT - 3 months ago

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

Apr 30, 2026, 4:05 PM EDT - 3 months ago

Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Akebia Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Akebia Therapeutics Proxy statement: Proxy filing

Apr 15, 2026, 8:00 AM EDT - 3 months ago

Akebia Therapeutics Proxy statement: Proxy filing

2026-04-13T12:52:17.000Z - 4 months ago

Akebia doses first participants in AKB-9090 trial

Apr 13, 2026, 8:00 AM EDT - 4 months ago

Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090

Apr 7, 2026, 8:00 AM EDT - 4 months ago

Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium

Apr 2, 2026, 10:00 AM EDT - 4 months ago

Akebia Therapeutics Transcript: R&D Day 2026

Apr 2, 2026, 10:00 AM EDT - 4 months ago

Akebia Therapeutics Slides: FY 2026

Apr 1, 2026, 4:05 PM EDT - 4 months ago

Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors

Mar 19, 2026, 4:05 PM EDT - 4 months ago

Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026

Mar 9, 2026, 8:00 AM EDT - 5 months ago

Akebia Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 8:00 AM EST - 5 months ago

Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference

Feb 27, 2026, 6:00 AM EST - 5 months ago

Akebia Therapeutics Slides: Corporate presentation

Feb 26, 2026, 8:00 AM EST - 5 months ago

Akebia Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:00 AM EST - 5 months ago

Akebia Therapeutics Annual report: Q4 2025

Feb 26, 2026, 8:00 AM EST - 5 months ago

Akebia Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 7:00 AM EST - 5 months ago

Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights

2026-02-25T12:25:29.000Z - 5 months ago

Akebia price target lowered to $4 from $5 at BTIG

Feb 19, 2026, 8:00 AM EST - 5 months ago

Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights

Feb 12, 2026, 9:30 AM EST - 6 months ago

Akebia Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

2026-02-06T11:56:25.000Z - 6 months ago

Akebia price target lowered to $4 from $6 at Piper Sandler

Feb 4, 2026, 8:00 AM EST - 6 months ago

Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

2026-01-12T13:52:21.000Z - 7 months ago

Akebia announces corporate updates, 2026 pipeline outlook

Jan 12, 2026, 8:00 AM EST - 7 months ago

Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook

2026-01-06T13:22:48.000Z - 7 months ago

Akebia announces first patient dosed in Phase 2 trial of praliciguat

Jan 6, 2026, 8:00 AM EST - 7 months ago

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)

Dec 2, 2025, 4:30 PM EST - 8 months ago

Akebia Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-12-01T12:21:08.000Z - 8 months ago

Akebia Therapeutics announces establishment of rare kidney disease pipeline

QTTB

2025-12-01T12:11:17.000Z - 8 months ago

Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront

QTTB

2025-12-01T12:05:21.000Z - 8 months ago

Q32 Bio sells complement inhibitor ADX-097 to Akebia

QTTB

Dec 1, 2025, 7:00 AM EST - 8 months ago

Akebia Announces Establishment of Rare Kidney Disease Pipeline

Dec 1, 2025, 7:00 AM EST - 8 months ago

Q32 Bio Sells Complement Inhibitor ADX-097

QTTB

Nov 24, 2025, 8:00 AM EST - 9 months ago

Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 17, 2025, 7:00 AM EST - 9 months ago

Akebia Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 10, 2025, 3:00 PM EST - 9 months ago

Akebia Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 8:00 AM EST - 9 months ago

Akebia Therapeutics Earnings Call Transcript: Q3 2025

Nov 10, 2025, 8:00 AM EST - 9 months ago

Akebia Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 8:00 AM EST - 9 months ago

Akebia Therapeutics Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 9 months ago

Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 6:30 PM EST - 9 months ago

Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs

Nov 4, 2025, 8:00 AM EST - 9 months ago

Akebia Therapeutics to Present at Upcoming Investor Conferences

Oct 30, 2025, 8:00 AM EDT - 9 months ago

Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights

2025-10-30T10:11:16.000Z - 9 months ago

Akebia price target lowered to $6 from $8 at H.C. Wainwright

2025-10-28T20:45:13.000Z - 9 months ago

Akebia says not in alignment with FDA on path forward for VALOR clinical trial

Oct 28, 2025, 4:30 PM EDT - 9 months ago

Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients

Oct 20, 2025, 8:08 AM EDT - 10 months ago

Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025

Sep 8, 2025, 12:00 PM EDT - 11 months ago

Akebia Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 8:00 AM EDT - 11 months ago

Akebia Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 2, 2025, 4:05 PM EDT - 11 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2025-08-21T12:21:04.000Z - 1 year ago

Akebia, IRC announce broad availability of Vafseo across IRC dialysis clinics

Aug 21, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics

Aug 13, 2025, 1:30 PM EDT - 1 year ago

Akebia Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Present at Canaccord Genuity's 45th Annual Growth Conference

Aug 4, 2025, 8:00 AM EDT - 1 year ago

Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights

Jul 14, 2025, 10:00 AM EDT - 1 year ago

Akebia Therapeutics Transcript: H.C. Wainwright 4th Annual Kidney Virtual Conference

Jul 8, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

Jun 30, 2025, 7:00 AM EDT - 1 year ago

Akebia Therapeutics Slides: Corporate Presentation

Jun 5, 2025, 8:45 AM EDT - 1 year ago

Akebia Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 8:00 AM EDT - 1 year ago

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

May 28, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

May 27, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025

May 20, 2025, 2:30 PM EDT - 1 year ago

Akebia Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 8, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings Call Transcript: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings release: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Proxy statement: Proxy Filing

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

Mar 19, 2025, 10:17 PM EDT - 1 year ago

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

Mar 19, 2025, 4:01 PM EDT - 1 year ago

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings Call Transcript: Q4 2024

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Annual report: Q4 2024

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings release: Q4 2024

Mar 13, 2025, 7:00 AM EDT - 1 year ago

Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

Mar 6, 2025, 8:00 AM EST - 1 year ago

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

Jan 21, 2025, 7:00 AM EST - 1 year ago

Akebia Therapeutics Slides: Investor Presentation

Jan 16, 2025, 10:30 AM EST - 1 year ago

Akebia Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 16, 2025, 10:30 AM EST - 1 year ago

Akebia Therapeutics Slides: FY 2025

Jan 13, 2025, 8:00 AM EST - 1 year ago

Akebia Therapeutics Announces Multiple Positive Business Updates

Dec 18, 2024, 8:00 AM EST - 1 year ago

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

HarryA123 Aug. 4 at 3:09 AM

$AKBA 1.27 dawg.

1 · Reply

MB76 Aug. 3 at 10:10 PM

4 · Reply

Noname2022 Aug. 3 at 9:50 PM

3 · Reply

Harrisford222 Aug. 3 at 9:38 PM

$AKBA Thats nice but WHAT COUNTS are hard revenue numbers. No hopes or wet dreams. The fact we see posts like the one below are additional clues that Q2 ist again disappointing...

2 · Reply

IberianBullish Aug. 3 at 9:37 PM

$AKBA

0 · Reply

ROCKET123 Aug. 3 at 9:36 PM

0 · Reply

Holy_boy Aug. 3 at 9:27 PM

$AKBA

4 · Reply

Noname2022 Aug. 3 at 9:09 PM

$CRMD $DVA $FMS $AKBA https://freseniusmedicalcare.com/content/dam/fresenius-medical-care/global/en/03_investors/pdf/03_publications/2026/q2/FME_Q2_2026_Analyst_Presentation.pdf

1 · Reply

Invest2live Aug. 3 at 8:57 PM

$CPIX 304% already; congrats 🔆🌿🌟 Checkout $HUMA and $AKBA excellent value now.

0 · Reply

MB76 Aug. 3 at 8:53 PM

$AKBA Clown still posting back and forth with himself!!!

1 · Reply

Harrisford222 Aug. 3 at 8:41 PM

$AKBA WORD!

1 · Reply

roomza Aug. 3 at 8:37 PM

$AKBA we must be close with these losers hanging around!⬇️

0 · Reply

TheGreedyGrinch Aug. 3 at 8:30 PM

$AKBA Stop saying this stock is down. This stock is not down. It's trading at it's true value.

0 · Reply

Noname2022 Aug. 3 at 8:28 PM

$CRMD $AKBA $FMS $DVA

0 · Reply

Zackwheat Aug. 3 at 8:28 PM

$AKBA it is so quiet. i am not a chart person can someone please let me know if shorts are accumulating. thank you

0 · Reply

TheGreedyGrinch Aug. 3 at 8:27 PM

$AKBA

0 · Reply

KarlDieGlatze Aug. 3 at 8:27 PM

$AKBA We have just ONE MAN to BLAME for the constant refusal to treat this biotech company with the same "value" based respect like companies without a fraction of the existing business lines--ongoing revenue near "profit!"--let alone the opportunities this Company has in front of it! His name is John P. Butler, and he should be removed as soon as possible or else shareholders might continue to suffer inexhaustible pain for him being the face associated with our investment!

0 · Reply

Walleye001 Aug. 3 at 8:18 PM

$AKBA With a rebel yell MOAR MOAR MOAR

0 · Reply

Quinnlucky Aug. 3 at 8:17 PM

$AKBA I think Auryxia comes in around $35M while Vafseo delivers at least $25M. With analyst estimates of just $48M in total revenue and EPS of -$0.04 (which is ridiculous) this will be an easy double beat. I’m looking forward to the earnings call. Good luck to all!

1 · Reply

the_gov Aug. 3 at 8:07 PM

$AKBA https://ir.akebia.com/news-releases/news-release-details/akebia-therapeutics-announces-initiation-phase-2-basket-trial

0 · Reply

ae1213 Aug. 3 at 7:11 PM

$AKBA algo trading whole day - total bs!

0 · Reply

HarryA123 Aug. 3 at 7:01 PM

$AKBA @Mr_Pithy is it up or down? Be honest. I will help you... so, when the %number is red... it means the stock price is? going...dooooooowwwww....what? Far from $30.

1 · Reply

Market Cap	354.10M
Revenue (ttm)	236.20M
Net Income (ttm)	-5.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2.27%
Debt to Equity Ratio	1.79

Volume	2,095,800
Avg Vol	4,462,526
Day's Range	N/A - N/A
Shares Out	268.26M
Stochastic %K	71%
Beta	0.23
Analysts	Strong Sell
Price Target	$4.20